27.04.2011 • News

J&J To Buy Synthes For $21.5 Billion

U.S. healthcare conglomerate Johnson & Johnson is expected to announce a $21.5 billion deal to buy Swiss medical device maker Synthes on Wednesday, the Wall Street Journal said, citing people familiar with the matter.

The deal is expected to value Synthes at 159 swiss francs ($180.51) a share, the Journal said, citing one person familiar with the matter.

Shares of Synthes closed at 146.50 Swiss francs on Tuesday.

Last week, Synthes confirmed it was in merger talks with J&J about a deal that would be J&J's largest-ever acquisition and reshape the medical devices industry.

The Journal said J&J is expected to pay one-third cash and the remainder in stock as part of the deal.

Synthes declined to comment on the Journal report to Reuters. J&J could not immediately be reached for comment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read